Patients' Attitudes to Unproven Therapies in Treating COVID-19 Merit Evaluation

Area of Science:

• Clinical Trials
• Public Health
• Medical Ethics

Background:

• Randomized controlled trials (RCTs) are crucial for evaluating COVID-19 treatments.
• Balancing rigorous evidence generation with timely patient access to investigational therapies is a key challenge during pandemics.
• Ethical considerations, including risk-benefit assessments, are paramount for approving and utilizing trial drugs.

Discussion:

• An electronic survey revealed significant patient interest in unproven COVID-19 trial drugs.
• Preference for trial drugs increased with infection severity: 3.9% (mild), 31.1% (severe), and 54.2% (extremely severe).
• Findings suggest substantial patient receptivity to investigational treatments in critical conditions.

Key Insights:

• Patient willingness to use experimental COVID-19 treatments rises sharply with disease severity.
• A significant portion of patients with severe or extremely severe COVID-19 would consider unproven trial drugs.
• Survey data underscores the demand for accessible investigational therapies.

Outlook:

• Further research is needed to explore patient perspectives on clinical trial participation.
• Ethical frameworks must adapt to accommodate compassionate use and off-label considerations for investigational therapies.
• Future public health strategies should incorporate patient preferences in treatment access during emergencies.